Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
์ข
๋ชฉ ์ฝ๋ CAI
ํ์ฌ ์ด๋ฆCaris Life Sciences Inc
์์ฅ์ผJun 18, 2025
์ค๋ฆฝ์ผ2020
CEOMr. David Dean Halbert
์ง์ ์- -
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJun 18
์ฃผ์750 West John Carpenter Freeway
๋์IRVING
์ฆ๊ถ ๊ฑฐ๋์NASDAQ Global Select Consolidated
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ75039
์ ํ18667718946
์น์ฌ์ดํธhttps://www.carislifesciences.com/
์ข
๋ชฉ ์ฝ๋ CAI
์์ฅ์ผJun 18, 2025
์ค๋ฆฝ์ผ2020
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์